Background Atrial fibrillation (AF) is a growing epidemic. Current models of care delivery are inadequate in meeting the needs of the population with AF. Furthermore, quality of life is known to be poor in patients with AF and is associated with adverse patient outcomes. Objective The aim of...
SGLT2 inhibitors also reduced the risk of cardiac arrhythmias and atrial fibrillation/atrial flutter progression [54, 55]. Currently, the approved SGLT2 inhibitors are empagliflozin [56], canagliflozin [57], dapagliflozin [58], ertugliflozin [59], tofogliflozin [60], luseogliflozin [61] and ...
Development of atrial fibrillation (AF) increases the risk of morbidity and mortality. These sequelae include: (1) an irregularly irregular rhythm that may result in uncomfortable palpitations and emotional distress; (2) loss of atrioventricular synchronous contraction, which impairs cardiac hemodynamics a...
Other tachyarrhythmias observed following PPGL resection may include atrial fibrillation, atrial flutter, and occasionally life-threatening ventricular fibrillation. Management of tachyarrhythmia is based on a patient's hemodynamic stability, presence or absence of narrow or wide complex QRS, and regular or...